GCC19CART
Relapsed/Refractory Metastatic Colorectal Cancer (mCRC)
Phase 1Active
Key Facts
Indication
Relapsed/Refractory Metastatic Colorectal Cancer (mCRC)
Phase
Phase 1
Status
Active
About Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a clinical-stage biotech pioneering CAR-T therapies for solid tumors, a significant unmet medical need. The company's core asset is its proprietary CoupledCAR® platform, which underpins its lead program, GCC19CART, for metastatic colorectal cancer, showing promising early clinical response rates. ICT has built a multi-platform technology suite including INSTACAR™ and ARMOREDCAR™ to support the development of enhanced cellular immunotherapies. As a private company, it is advancing a pipeline focused on translating its platform technologies into potential first-in-class treatments for challenging cancers.
View full company profile